Confo Therapeutics enters into drug discovery collaboration with Roche
Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialisation. The financial terms include an upfront payment, pre-clinical milestones and research funding to Confo Therapeutics totaling €6 million over the initial 30 months period of the collaboration. In addition, Confo Therapeutics is eligible to receive up to €81.5 million of payments for certain development, regulatory and commercial milestones, plus tiered royalties on the annual net sales of any products resulting from the collaboration.
“Securing this partnership with Roche is another significant corporate milestone for Confo Therapeutics,” said Dr. Cedric Ververken, CEO. “The decision by a global pharmaceutical company to work with Confo Therapeutics further validates the strength of our proprietary Confo technology and the capabilities of our team. It also strengthens our resolve to vigorously pursue our own proprietary product pipeline in addition to enabling our partners to develop valuable medicines for patients.”
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.